Capital Increase in Genmab as a Result of Employee Warrant Exercise
November 20, 2018 12:20 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; November 20, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 7,588 shares as a consequence of the exercise of employee...
Data from Phase III MAIA Study of Daratumumab Accepted for Presentation at Annual Meeting of American Society of Hematology
November 20, 2018 09:07 ET
|
Genmab A/S
Media Release Data from Phase III MAIA study in front line multiple myeloma accepted as Late-breaking Abstract for oral presentation at ASH Annual Meeting Copenhagen, Denmark; November 20, 2018 –...
CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX® (daratumumab)
November 19, 2018 07:21 ET
|
Genmab A/S
Media Release CHMP issued positive opinion on split dosing regimen for DARZALEX Final decision from European Commission expected in the coming monthsOpinion supported by data from EQUULEUS...
Genmab Announces Financial Results for the First Nine Months of 2018
November 14, 2018 11:00 ET
|
Genmab A/S
November 14, 2018; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2018 Highlights USD 1,441 million in net sales of DARZALEX® (daratumumab), resulting in royalty...
Genmab to Present at the Jefferies 2018 London Healthcare Conference
November 08, 2018 08:57 ET
|
Genmab A/S
Media Release Copenhagen, Denmark; November 8, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the company’s CEO, Jan van de Winkel, Ph.D., will present an update at the Jefferies 2018...
Genmab Announces Data to be Presented at 2018 ASH Annual Meeting
November 01, 2018 09:16 ET
|
Genmab A/S
Media Release Thirty-five total abstracts on Genmab owned and partnered programs scheduled for presentation at ASHThree abstracts related to Genmab owned programs: DuoBody®-CD3xCD20 &...
Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
October 29, 2018 16:52 ET
|
Genmab A/S
Company Announcement Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone in front line multiple myeloma met the primary endpoint (PFS) at a pre-planned interim...
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
October 21, 2018 17:46 ET
|
Genmab A/S
Company Announcement Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of stringent...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2018
October 16, 2018 06:45 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX in the third quarter of 2018 totaled USD 498 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to be Presented at ESMO 2018 Congress
October 08, 2018 18:51 ET
|
Genmab A/S
Media Release Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer Copenhagen, Denmark and BOTHELL, Wash., October 9, 2018 –...